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Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based
stereotactic radiotherapy with rectal displacement
Abstract
Background: MOSFET dosimetry is a method that has been used to measure in-vivo doses during
brachytherapy treatments and during linac based radiotherapy treatment. Rectal displacement devices
(RDDs) allow for safe dose escalation for prostate cancer treatment. This study used dual MOSkin
detectors to assess real-time in vivo rectal wall dose in patients with an RDD in place during a high dose
prostate stereotactic body radiation therapy (SBRT) boost trial. Methods: The PROMETHEUS study
commenced in 2014 and provides a prostate SBRT boost dose with a RDD in place. Twelve patients
received two boost fractions of 9.5-10 Gy each delivered to the prostate with a dual arc volumetric
modulated arc therapy (VMAT) technique. Two MOSkins in a face-to-face arrangement (dual MOSkin)
were used to decrease angular dependence. A dual MOSkin was attached to the anterior surface of the
Rectafix and read out at 1 Hz during each treatment. The planned dose at each measurement point was
exported from the planning system and compared with the measured dose. The root mean square error
normalised to the total planned dose was calculated for each measurement point and treatment arc for
the entire course of treatment. Results: The average difference between the measured and planned doses
over the whole course of treatment for all arcs measured was 9.7% with a standard deviation of 3.6%. The
cumulative MOSkin reading was lower than the total planned dose for 64% of the arcs measured. The
average difference between the final measured and final planned doses for all arcs measured was 3.4% of
the final planned dose, with a standard deviation of 10.3%. Conclusions: MOSkin detectors were an
effective tool for measuring dose delivered to the anterior rectal wall in real time during prostate SBRT
boost treatments for the purpose of both ensuring the rectal doses remain within acceptable limits during
the treatment and for the verification of final rectal doses.
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Real-time in vivo rectal wall dosimetry
using MOSkin detectors during linac based
stereotactic radiotherapy with rectal
displacement
Kimberley Legge1* , Peter B. Greer1,2, Daryl J. O’Connor1, Lee Wilton2, Matthew Richardson2, Perry Hunter2,
Alex Wilfert2, Jarad Martin2, Anatoly Rosenfeld3 and Dean Cutajar3

Abstract
Background: MOSFET dosimetry is a method that has been used to measure in-vivo doses during brachytherapy
treatments and during linac based radiotherapy treatment. Rectal displacement devices (RDDs) allow for safe dose
escalation for prostate cancer treatment. This study used dual MOSkin detectors to assess real-time in vivo rectal
wall dose in patients with an RDD in place during a high dose prostate stereotactic body radiation therapy (SBRT)
boost trial.
Methods: The PROMETHEUS study commenced in 2014 and provides a prostate SBRT boost dose with a RDD in
place. Twelve patients received two boost fractions of 9.5–10 Gy each delivered to the prostate with a dual arc
volumetric modulated arc therapy (VMAT) technique. Two MOSkins in a face-to-face arrangement (dual MOSkin)
were used to decrease angular dependence. A dual MOSkin was attached to the anterior surface of the Rectafix
and read out at 1 Hz during each treatment. The planned dose at each measurement point was exported from the
planning system and compared with the measured dose. The root mean square error normalised to the total
planned dose was calculated for each measurement point and treatment arc for the entire course of treatment.
Results: The average difference between the measured and planned doses over the whole course of treatment for
all arcs measured was 9.7% with a standard deviation of 3.6%. The cumulative MOSkin reading was lower than the
total planned dose for 64% of the arcs measured. The average difference between the final measured and final
planned doses for all arcs measured was 3.4% of the final planned dose, with a standard deviation of 10.3%.
Conclusions: MOSkin detectors were an effective tool for measuring dose delivered to the anterior rectal wall in
real time during prostate SBRT boost treatments for the purpose of both ensuring the rectal doses remain within
acceptable limits during the treatment and for the verification of final rectal doses.
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Background
Prostate cancer shows a radiation response consistent
with a low α/β ratio, indicating that hypofractionated
treatment schedules may increase the effectiveness of
treatment [1, 2]. Hypofractionation includes the delivery
of higher dose fractions to boost the total dose prior to
or following conventionally fractionated treatment. Delivery of a boost dose using high dose rate (HDR)
brachytherapy in combination with conventionally fractionated external beam radiation therapy (EBRT) has
been shown to improve tumour control rates when compared with conventionally fractionated EBRT alone [3–
5]. EBRT is far more accessible than brachytherapy in
Australia, and low rates of rectal and urinary toxicity
along with good biological response rates have been observed in patients who received a boost dose delivered
using an SBRT technique [6–8].
Rectal complications can arise as a result of radiation
therapy for prostate cancer, and delivery of higher doses
through hypofractionation increases the risk of damage
to surrounding healthy tissues [9]. The risk and severity
of rectal toxicities has been correlated with the volume
of rectal wall exposed to high doses of radiation [10].
Use of dose volume constraints in planning and daily
imaging to enable reduced margins are the most effective ways to reduce rectal dose, but rectal sparing devices
such as injected spacer materials and the Rectafix rectal
retractor have also been used to allow for safe dose escalation [11]. The Rectafix system (Fig. 1) uses a rod
which is inserted into the patient’s rectum. The rod is
then moved posteriorly on the vertical column and
locked in place to manually move the rectum away from
the prostate. The vertical column is marked to allow reproducible retraction. The Rectafix has been found to
provide an average increase in separation of 0.5 cm and
to assist in immobilising the rectal wall by preventing
changes in filling by gas or faeces [12].

Fig. 1 The Rectafix system
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Changes in bladder or rectal volume during treatment
can affect the dose coverage of the prostate and increase
the dose to healthy tissues. One way to monitor the effect of any motion is real-time in-vivo dosimetric monitoring during treatment. Previous studies in this area
have used plastic scintillation detectors and MOSFET
based dosimeters in phantoms [13–16]. Plastic scintillation detectors attached to an endorectal balloon inserted
in an anthropomorphic prostate phantom were used by
Archambault et. al. to provide dose measurements every
150 ms during eight field intensity modulated radiation
therapy treatments. In a field by field comparison, plastic
scintillation detectors were found to agree with treatment planning system doses to within 0.5% [13].
MOSkin detectors are MOSFET based dosimeters. They
have successfully been used to measure urethral dose inside a catheter placed within a gel phantom simulating a
typical HDR brachytherapy treatment, with two MOSkin
detectors used in a face to face arrangement (a dual
MOSkin) found to be more accurate than a single
MOSkin detector [14]. Dose to the anterior rectal wall in
a phantom study of tomotherapy prostate boost dose
while attached to a replica Rectafix rod has also been
verified with MOSkins, with all dual MOSkins used in
this study agreeing with treatment planning system dose
to within ±5% when placed in a high dose gradient region [15]. MOSkins have been integrated into a transrectal ultrasound probe of the kind used to guide interstitial
needle insertion during HDR brachytherapy treatment.
MOSkin measurements taken during three HDR brachytherapy treatment deliveries to a phantom resulted in an
average discrepancy of −0.6 ± 2.6% between the measured and planned doses [16].
There have been very limited in-vivo patient dosimetry
studies, however, in-vivo measurements have been performed during HDR brachytherapy treatments and
EBRT treatments. Plastic scintillation detectors attached
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to an endorectal balloon were used by Wootton et al. to
measure dose to the rectal wall over 142 prostate EBRT
fractions for five patients. The average difference between measured doses and doses calculated on day of
treatment CT scans was −0.4 ± 2.8% [17]. In a study of
12 patients by Carrara et. al., MOSkins integrated into a
transrectal ultrasound probe were shown to accurately
measure dose delivered to the rectal wall during HDR
brachytherapy treatments. The MOSkin measured doses
were found to align more closely with delivered doses
reconstructed after treatment than with planned doses
in this case. The average absolute difference between
MOSkin measured doses and reconstructed doses was
3.6 ± 1.9%, while the difference between MOSkin measured doses and planned doses was 6.7 ± 5.1%, with a
total measurement uncertainty of 5.7%, demonstrating
their potential for use in detecting treatment delivery errors [18]. However, assessment of rectal dose delivered
during EBRT boost treatments using MOSkin detectors
within patients has not been investigated to date, and
previous studies have only compared measured doses
with total planned doses for each field or treatment.
The aim of this work was to examine the feasibility of
determining real-time in vivo rectal wall dose during
prostate SBRT with a rectal retractor by monitoring during treatment with a dual MOSkin detector. Measured
doses were compared with planned doses across the
whole course of each treatment arc delivered to provide
a measure of the accuracy of delivery, including treatment plan dose calculation and patient setup errors.

Methods
1. Patient and treatment details
The PROstate Multicentre External beam
radioTHErapy Using Stereotactic boost
(PROMETHEUS) study commenced in late 2014
and provides an EBRT boost dose consisting of two
fractions to patients prior to a conventionally
fractionated course of EBRT. A Rectafix rectal
sparing device was in place during both boost
fractions for the patients in this study. Twelve
patients with intermediate to high risk prostate
cancer (median age 72) consented to the ethics
board approved study. EBRT boost treatments were
planned using the Eclipse treatment planning system
(version 11) and were delivered using either a Varian
Clinac iX linear accelerator with a 6 MV photon
beam at a maximum dose rate of 600 MU/min or
using a Varian Truebeam linear accelerator with a 10
MV beam with a maximum dose rate of 600 MU/
min or 10 MV flattening filter free photon beam
with a maximum dose rate of 2400 MU/min. Six
patients received a boost dose of 9.5 Gy per fraction
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and six patients received a boost dose of 10 Gy per
fraction. All patients were treated with a Rectafix
system in place. The Rectafix system is shown in
Fig. 1. Patients received a pre-treatment cone beam
computed tomography (CBCT) scan to check Rectafix positioning and bladder and rectal filling and
were aligned using implanted gold fiducial markers.
The prostate position in patients treated on the
Truebeam was monitored using triggered two dimensional kilovoltage images taken every 3 s during
treatment. Mid-treatment CBCT scans for repositioning were taken for all patients treated on the
Clinac, and for patients treated on the Truebeam for
whom the triggered imaging indicated prostate displacement had occurred. All patients received a
post-treatment CBCT scan.
2. MOSkin Design
MOSkin detectors, developed at the Centre for
Medical Radiation Physics, University of
Wollongong, are MOSFET based detectors designed
to measure dose at the air-skin interface and have an
active volume of 4.8 × 10−6 mm3 with a gate oxide
thickness of 0.55 μm [19] and a water equivalent
depth of 0.07 mm. This small volume makes them
desirable for measurements in high dose gradient regions, [20] such as the anterior rectal wall in a prostate SBRT boost plan. MOSkin detectors provide
temperature independent measurements between 15
and 40 °C [21] and have reproducible sensitivity for
fraction sizes up to 10 Gy [20]. Two MOSkins in a
face-to-face arrangement (a dual MOSkin) have been
found to reduce angular dependence resulting from
the geometrical construction of the detector [22].
The dual MOSkin threshold voltage can be read out
at 1 Hz and real-time readout software developed by
the University of Wollongong can be used to convert the voltage to dose and display the cumulative
dose delivered to the MOSkin as treatment progresses. MOSkin detectors are visible on cone beam
CT (CBCT) scans. The MOSkin readout unit a dual
MOSkin attached to the Rectafix rod appear in
Fig. 2.
3. Calibration and Testing
Prior to treatment using the linear accelerator, dual
MOSkin detectors were calibrated at the energy and
dose rate that was to be used for patient treatment.
Dual MOSkins were aligned to isocentre using lasers
and placed under 1.5 cm of solid water for 6 MV
treatments, and under 2.5 cm of solid water for 10
MV treatments, with a 100 cm source to surface
distance, so that the MOSkin would lie at the depth
of dose maximum. A field size of 10 cm × 10 cm and
collimator angle of 0° was used. Calibration was
performed by delivering 20 cGy, as determined by
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Fig. 2 The Clinical Semiconductor Dosimetry System used to read
out MOSkin detectors and a dual MOSkin detector attached to the
Rectafix rod

nominal machine output, to the dual MOSkin
arrangement in five separate irradiations. The dual
MOSkin was then inverted, placing both detectors in
inverse orientation so that the other detector was
closest to the beam, and another five irradiations of
20 cGy were delivered.
To determine a calibration factor for each dual
MOSkin, the reading for each individual MOSkin
detector at 30 s after beam off was recorded for
each delivery, resulting in 20 total voltage values, five
from each detector (×2 detectors) in the initial
orientation and five from each detector in the
inverse orientation. The 20 values obtained were
then averaged. A calibration factor, CF (mV/cGy)
was then obtained by dividing the average threshold
voltage shift (ΔVav mV) by the delivered dose
(20 cGy) as shown in Eq. 1.
CF ¼

ΔV av mV
20 cGy

ð1Þ

Dual MOSkin detectors were tested for angular
dependence by irradiation in the centre of a solid
water cylinder 20 cm in diameter. The cylinder was
raised 5 cm from the couch using solid water blocks
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for supports. The dual MOSkin was rotated relative
to the beam and irradiated after every 30° rotation.
MOSkin detectors were also tested for dose linearity
from 10 to 200 cGy and dose rate dependence from
100 MU/min to 600 MU/min at 1.5 cm depth in
solid water using a Varian Clinac iX linear
accelerator.
4. Phantom Study
As a final end-to-end test, a dual MOSkin was
placed in a specially made insert in a CIRS 801-P
Virtually Human Male Pelvis phantom (CIRS Inc.,
Norfolk, VA). A CT scan of the phantom with the
insert in position was acquired and a 9.5 Gy dual arc
VMAT plan was transferred to the CT scan and calculated. The treatment plan on the phantom with
the specially made insert is shown in Fig. 3.
The phantom was aligned with CBCT using a
phantom insert with fiducial markers. This insert
was then carefully removed and the insert with a
dual MOSkin device was placed in the phantom.
The plan was delivered using a Varian Clinac iX
linear accelerator and the dual MOSkin was read out
at 1 Hz during delivery. The same steps as outlined
below in part six were used to compare the MOSkin
measured dose with the planned dose extracted
from the treatment planning system.
5. Treatment Delivery
Prior to each treatment fraction, a dual MOSkin
detector was attached to the anterior surface of the
Rectafix rod using sterile adhesive wraps, as shown
in Fig. 2. The entire rod was then covered with a
condom to ensure that the risk of patient contact
with the device was minimised. Each dual MOSkin
was used for a single treatment fraction and then
discarded. The location of the MOSkin was chosen
by measuring within the Eclipse planning system, in
the superior-inferior direction, the distance from the
axial plane in which the collar of the rod appears to
the axial plane in which the centre of the planning
target volume (PTV) occurs so that the location was
reproducible and as close to the centre of the PTV
as possible.
The dual MOSkin was attached to the clinical
semiconductor dosimetry system, which was
attached to a laptop computer. Real-time readout
software called FETch (Centre for Medical Radiation
Physics, University of Wollongong) was used on the
laptop for readout. The Rectafix, with attached dual
MOSkin, was inserted into the patient prior to alignment. Detectors were inside the patient for over
10 min prior to irradiation, giving the detectors time
to equalise with patient temperature. Detectors were
zeroed immediately prior to treatment delivery and
voltages read out from both detectors in the dual
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Fig. 3 Dose plan on phantom with specially made insert for dual MOSkin detector

MOSkin at 1 Hz during delivery of each two arc
treatment. EPID images were acquired during
treatment at 15.26 Hz using a research framegrabber computer. The gantry angle for each
image was recorded by the imaging system so
that the position of the gantry with time was
known.
Following delivery, MOSkin readouts were imported
into a spreadsheet. The doses recorded by each of
the individual detectors making up the dual detector
were averaged and the result divided by the
detector’s calibration factor.
6. Extraction of Planned Dose and Comparison
Within the Eclipse treatment planning system, the
location of the active area of the MOSFET in the
CBCT acquired at the end of each fraction was
marked. Each of these CBCTs was then manually
registered to the patient’s planning CT. A
verification point was then placed on the planning
CT at the location of the MOSFET, yielding two
verification points per patient, one for each prostate
SBRT boost fraction. Figure 4 shows a posttreatment CBCT scan of a patient with the active
area of the MOSkin marked.

For patients treated using a 6 MV or 10 MV beam
with a flattening filter, a verification plan was created
in the Eclipse treatment planning system with the
treatment split into sub-arcs, each of 5.2°. The dose
file for each sub-arc and the plan file were then
exported from the system. For 10 MV flattening filter free beams, the version of the planning system
available was unable to automatically split patient
plans into sub-arcs. Five partial treatment plans were
created for each of these patients, evenly splitting
each arc by control points to obtain five cumulative
dose points for each treatment. Following export of
all dose and plan files, in-house software was used to
extract the dose and gantry angle for each arc at the
location of the MOSkin verification points. The position of the gantry with time was determined using
spline interpolation from the gantry angles recorded
in the header of the EPID images acquired at
15.26 Hz during treatment.
Planned dose at the verification point and MOSkin
measured dose were then plotted as a function of
time over the whole course of each treatment
fraction. The root mean square error (RMSE) was
found for each treatment fraction to compare the
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Fig. 4 Marker at MOSkin location on CBCT scan taken following a patient treatment. The CTV and 50% isodose regions appear in purple

MOSkin measured dose with the planning system
dose across the whole treatment time. The RMSE
value was normalised to the final planning system
dose for each fraction to enable comparison between
different patient plans.

Results
1. Calibration and Testing
The average calibration factor obtained for the dual
MOSkins used for phantom and patient treatments
was 2.30 ± 0.07 mV/cGy. The maximum range of

Fig. 5 Angular dependence results for dual MOSkin detector

MOSkin responses for dose rates varying from 100
MU/min to 600 MU/min was ±2.6% for all dose
rates measured. When varying the dose delivered, all
MOSkin readings were within ±2.0%, indicating a
linear response to dose.
The results of the angular dependence testing
appear in Fig. 5. The error bars are one standard
deviation from the mean of two measurements taken
at each angle. The MOSkin readings were
normalised to the average MOSkin response for
angles from 0 to 330°. All measurements were
within ± 2.9% of the average MOSkin reading.
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2. Phantom Study
The results of the measurements performed in the
anthropomorphic phantom appear in Table 1. The
final dose difference was obtained by calculating the
cumulative measured dose minus the final planned
dose.
Figure 6 presents the dose measured by the dual
MOSkin inserted into the anthropomorphic
phantom and the planned dose at the MOSkin
location.
3. Patient Results
Table 2 presents the normalised RMSE as a
percentage of final planned dose for each patient
treatment. RMSE comparison was performed so that
the practicality of using MOSkin detectors to validate
dose delivery in real time could be assessed. RMSE
compares the measured and planned doses across the
entire treatment delivery. The position of the MOSkin
in fraction one was an average of 1.08 ± 0.66 cm from
the position of the MOSkin during fraction 2.
The average RMSE difference between the measured
and planned system doses determined over all
fractions measured in this study was 9.7% with a
standard deviation of 3.6%. The cumulative MOSkin
reading was lower than the total planned dose for
64% of the arcs measured. This is illustrated in
Fig. 7, which shows the cumulative measured dose
minus the total planned dose as a percentage of total
planned dose for each patient arc. The average
difference between the final measured and final
planned doses for all arcs measured was −3.4% of
the final planned dose, with a standard deviation of
10.3%. The average distance to agreement from the
MOSkin location on the plan was 0.14 ± 0.11 cm
across all patients, with a maximum distance to
agreement of 0.47 cm.
Figure 8 shows the comparison of measured and
planned dose for a patient treated using a 6 MV
beam, so the plan was automatically split into subarcs of 5.2° in the Eclipse planning system.

the method used in this study could allow the delivered
dose to be compared to the planned dose in real time
during treatment, allowing for patient repositioning if
the measured dose exceeds a preselected dose level during treatment.
The angular dependence measurements for the MOSkin
performed in this study found a variation of ± 2.9% in
MOSkin dose measurements taken every 30° of rotation.
These results are in reasonable agreement with those
measured in a previous study using dual MOSkins by
Hardcastle et al., [20] who found a variation of ± 2.5% in
readings performed in rotation increments of 30°. The discrepancy in these values may be due to differing geometry
in the phantom setup or statistical fluctuations.
Uncertainty in the position of the MOSkin detector
and verification point are major sources of discrepancy,
as the detector is placed in a high dose gradient region
during treatment. Across the rectal wall, the dose can
decrease by 4.3% over a distance of 1 mm, as measured
in the treatment planning system, meaning that a small
discrepancy in the positioning of the verification point
in the plan could mean a large difference in the dose
exported from the planning system. While the MOSkin
is visible on CBCT scans, precisely placing the verification point on the active area of the MOSkin is difficult,
as the detector appears as a long strip with no delineation between the active area and the tail of the MOSkin,
and the CBCT resolution makes it difficult to discern
the exact location of the end of the detector. Patient
shifts occurred between treatment arcs in nearly all cases
measured, and patient anatomy in the area of the prostate
is mobile, therefore, the verification point selected from the
end of treatment CBCT does not indicate the location of
the MOSkin detector throughout the entire course of treatment. The average difference between the MOSkin location

Discussion
MOSkin detectors attached to a Rectafix were used to
measure anterior rectal wall dose in real time during
prostate SBRT boost treatments. Measured doses were
compared with planned doses extracted at the position
of the MOSkin post treatment. Small modifications to
Table 1 Comparison of measured and planned doses for dual
MOSkin measurements in an anthropomorphic phantom
Treatment
Arc

Normalised RMSE (% of
final planned dose)

Total dose
Final dose
difference (cGy) difference (%)

Arc 1

3.3

1.1

2.4

Arc 2

2.1

−2.7

−6.4

Fig. 6 Plots of measured and planned dose obtained during
delivery of a dual arc plan to a dual MOSkin in an
anthropomorphic phantom
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Table 2 Normalised RMSE comparison of measured and
planned doses for each treatment fraction
Patient

Normalised RMSE Fraction
1 (% of final planned dose)

1

8.9

13.2

2

11.8

8.4

3

11.4

13.9

4

7.6

17.3

5

5.3

8.5

6

9.3

15.0

7

15.0

–

8

4.6

6.6

9

7.0

15.5

10

8.4

6.5

11

6.4

6.7

12

8.7

7.8

Average

9.7

Standard
deviation

3.6

Normalised RMSE Fraction
2 (% of final planned dose)

on the pre-treatment CBCT and the post-treatment CBCT
was 0.55 ± 0.47 cm which could result in a dose difference
in that location of over 20%. The average distance to agreement of 0.14 ± 0.11 cm is well within this change in
MOSkin location, indicating that the dose discrepancies
likely result from the changing position of the MOSkin
throughout the treatment due to patient motion and repositioning based on imaging. No fluctuations in detector signal stability were observed due to patient motion.
Previous studies using MOSkins to measure dose in
phantoms [14, 16] during brachytherapy reported better

Fig. 7 Comparison of total planned dose and cumulative measured
dose per arc. The dose difference was calculated by determining the
cumulative measured dose minus the total planned dose for each
treatment arc
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agreement between total measured and planned doses
than the patient measurements reported here, as did a
phantom study of rectal wall dose measurement during
tomotherapy [15]. A phantom study using plastic scintillation detectors attached to endorectal balloons found
agreement between measured and planned doses to within
0.5%, [13] and plastic scintillation detectors measured rectal wall dose in patients during EBRT with the mean difference between measured and planned doses for each
patient ranging from −3.3 to 3.3% [17]. Measurements
taken using MOSkins in patients during brachytherapy
treatments found an average discrepancy between measured and planned doses of 6.3% with a standard deviation
of 4.7% [18]. The results of the in-patient measurements
reported here give a closer average agreement between
measured and planned doses than the previous MOSkin
study, 3.6%, with a larger standard deviation of 10.3%.
To adapt the method used here to allow for comparison of measured and planned dose in real time during
treatment, Rectafix and MOSkin positioning would need
to be consistent at simulation and for each fraction. At
present, Rectafix positioning is guided by patient tolerance on the day of treatment. Preparation prior to treatment would require less than half an hour of work per
patient to calibrate the MOSkin detectors and export the
planned dose at the location of the MOSkin on the
simulation CT. The planned dose with time could then
be imported into the MOSkin readout software prior to
treatment. The delivered dose could then be monitored in
real time and adjustments made if the measured dose differed from the planned dose by a predetermined amount.
Without these adjustments, the dose tolerance for any interruptions would need to be large, as small differences in
the MOSkin position result in large dose differences.

Fig. 8 Comparison of planned and MOSkin measured dose to the
anterior rectal wall as a function of time for each arc of a 9.5 Gy
prostate SBRT boost treatment delivered with a 6X flattened beam.
The planned dose has been exported in sub-arcs of 5.2°
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Conclusions
MOSkin detectors were used to measure dose to the anterior rectal wall in real time during prostate SBRT boost
treatments. The average RMSE dose difference over the
entire course of all arcs measured during this study was
9.7% with a standard deviation of 3.6%. Small modifications to the method presented here would allow MOSkins
to provide a dose alarm during SBRT treatments to avoid
increased dose to the rectum in the case of delivery errors.
Abbreviations
CBCT: Cone beam computed tomography; EBRT: External beam radiation
therapy; HDR: High dose rate; RDD: Rectal displacement device; RMSE: Root
mean square error; SBRT: Stereotactic body radiation therapy;
VMAT: Volumetric modulated arc therapy
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